Ameresco Q2: Revenue Beat, FCF Disaster, and the False Narrative That Drove a 28% Pop

The market just told itself a story about Ameresco. Revenue beat. EBITDA grew 12%. Backlog is strong. The stock jumped 28% after-hours on Monday, August 3. It's the kind of reaction that makes energy-infrastructure investors feel good - growth, execution, the future of the grid. And it's also the kind of reaction that happens when you look at the top line and skip the cash flow.

I've been very surprised by how the market rewarded Ameresco's second-quarter report while ignoring a trailing-twelve-month free cash flow burn of $326.4 million. That number is not a footnote. It's the headline.

Let's decompose what Ameresco actually reported.

Revenue came in at $515.5 million, roughly 9% above the prior-year quarter and above analyst expectations. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization - a rough proxy for operating cash generation before capital spending) rose 12% to $62.8 million. Non-GAAP earnings per share hit $0.20, meeting the consensus estimate. Ameresco updated its full-year non-GAAP EPS guidance to $1.15–$1.35, which is a modest raise from the $1.06–$1.28 range that was on the street.

These are respectable operating numbers. The awarded project backlog grew 20% year over year to $2.8 billion. Total project backlog sits at $5.3 billion. O&M (operations and maintenance) backlog exceeds $1.5 billion, which is the most defensible, predictable revenue Ameresco generates. And the $400 million joint venture with HASI - creating Neogenix Fuels, with Ameresco holding 70% - delivers $100 million to Ameresco for deleveraging and $300 million into the JV for growth.

So what went wrong?

Ameresco's trailing free cash flow is negative $326.4 million. Operating cash flow over the same period is negative $16.7 million, and capital expenditures came in at $309.7 million. The company is spending almost $310 million to build and operate its energy asset base - biogas plants, renewable natural gas facilities, efficiency projects - while barely breaking even on cash from operations. That means every quarter of growth is funded by debt or dilution, not by the business itself.

The balance sheet makes the constraint clear. Total debt stands at $3.53 billion against $1.11 billion in equity. That's a debt-to-equity ratio of 179%. Net debt (total debt minus cash) is $1.88 billion. Corporate leverage at 3.2x sits under the 3.5x covenant, which is technically fine - but the cushion is paper-thin for a company burning cash at this rate. Ameresco had $104 million in unrestricted cash at the end of the last reported quarter. That's roughly four months of capital spending. If capex stays near $310 million annually and operating cash flow doesn't materially improve, the company needs to keep borrowing or selling assets to fund its growth plan.

Here's the part that matters most for investors: Ameresco doesn't pay a dividend. It doesn't return capital to shareholders at all. For a company with a $1.2 billion market cap trading at 38 times trailing earnings and 81 times forward earnings, the entire investment thesis rests on the assumption that growth will eventually generate enough free cash flow to justify the valuation. That's a bet on the future, not a position on current economics.

Compare that to Brookfield Renewable Partners, which trades at a fraction of the earnings multiple and pays a 4.5% yield, or American Water Works, which has a 2.5% yield and generates positive free cash flow. These companies have the same exposure to the energy transition - renewable assets, infrastructure, long-term contracts - but they actually return cash to shareholders while they grow. Ameresco grows on leverage.

The false narrative here isn't that Ameresco's revenue is weak or that the energy transition is a scam. Revenue growth is real. Backlog growth is real. The federal government is a material customer, and the IRA's tax credit machinery is working. The false narrative is that a revenue beat justifies an 81x forward earnings multiple in a company with negative free cash flow, no dividend, and a balance sheet that's two bad quarters away from needing a capital raise.

There's also a structural timing risk. Ameresco's revenue is heavily back-loaded - roughly 60% of annual revenue falls in the second half of the year. The Q2 beat might look impressive in isolation, but it represents roughly 10% of what the company plans to deliver in 2026. That means three-quarters of the annual story hasn't happened yet, and the market just priced all of it into a 28% single-day move.

Insiders don't seem to think the pre-surge price was cheap either. Two directors sold 20,000 shares combined worth roughly $625,000 in May under 10b5-1 trading plans. Insider ownership at 45% is high, but selling at $30–$32 per share - well above today's $22.73 - tells you something about where leadership thinks the fair zone starts.

That being the case, I rate Ameresco as a Sell. The 28% pop turned a stretched valuation into a genuinely expensive one. The company has a real business with genuine growth drivers - federal spending, energy infrastructure demand, renewable natural gas expansion - but it hasn't proven that those drivers generate cash after capital spending. Until free cash flow turns meaningfully positive, until Ameresco starts returning capital to shareholders, or until the market stops pricing in three years of growth for a single earnings beat, there's no structural reason to hold.

In my opinion, the stock's current price reflects a narrative about where Ameresco could go, not what it's doing today. There's a difference, and it's worth the cost of a position.